Amgen stock analysis
Amgen (AMG) Stock Price & Analysis
AMG Stock Chart & Stats
- Day’s Range
- CHF 377.76 - CHF 388.34
- 52-Week Range
- CHF 226.36 - CHF 389.73
- Previous Close
- CHF 388.34
- Volume
- N/A
- Average Volume (3M)
- 4
- Market Cap
- CHF 204.13B
- Enterprise Value
- CHF 270.96B
- Total Cash (Recent Filing)
- CHF 13.19B
- Total Debt (Recent Filing)
- CHF 54.01B
- Price to Earnings (P/E)
- 26.8
- Beta
- 0.37
- Next Earnings
- Feb 09, 2027 (Est.)
- EPS Estimate
- 4.61
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.06%
Bulls Say, Bears Say
Bulls Say
Broad Portfolio Growth
Growth is broad rather than dependent on one product, with multiple therapies delivering double-digit gains and key drivers representing most product sales. This diversification supports more durable revenue expansion, improves commercial resilience, and gives Amgen a stronger base for continued investment.
Late-stage Pipeline Strength
Positive late-stage results across oncology, respiratory disease and Sjogren’s disease strengthen the pipeline’s potential to add future growth platforms. Multiple programs reduce reliance on existing products and support portfolio renewal as therapeutic needs and competitive conditions evolve.
Strong Profitability And Cash Generation
High margins and substantial operating and free cash flow provide internal funding for research, manufacturing capacity, acquisitions and shareholder returns. This cash-generative model gives Amgen flexibility to advance its pipeline while supporting ongoing commercial and operational investment.
Bears Say
Heavy Financial Leverage
Heavy leverage leaves Amgen more exposed if earnings weaken, because interest obligations and refinancing needs can absorb cash that might otherwise support innovation or shareholder returns. The relatively small equity base also amplifies financial risk when operating performance becomes less consistent.
Uneven Cash-flow Coverage
Although absolute cash generation is strong, declining free cash flow and inconsistent coverage indicate that conversion has not been uniformly dependable. Continued volatility could constrain debt reduction, investment capacity or capital returns if operating conditions become less favorable.
Reimbursement And Adoption Barriers
Reimbursement pressure outside the U.S. could limit access and slow the commercial ramp for MariTide, while treatment-management complexity may delay broader use of T-cell engagers. These barriers could reduce the pace at which pipeline opportunities translate into durable sales.
Amgen News
AMG FAQ
What was Amgen’s price range in the past 12 months?
What is Amgen’s market cap?
When is Amgen’s upcoming earnings report date?
How were Amgen’s earnings last quarter?
Is Amgen overvalued?
Does Amgen pay dividends?
What is Amgen’s EPS estimate?
How many shares outstanding does Amgen have?
What happened to Amgen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Amgen?
What is the TipRanks Smart Score and how is it calculated?
Amgen Stock Smart Score
Company Description
Amgen
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Bradway
- Employees
- 31,500
- Website
- www.amgen.com
- Address
- One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, US
Amgen (AMG) Earnings & Revenues
AMG Company Deck
AMG Earnings Call
Earnings Call SentimentPositive
The call was strongly optimistic, supported by 8% revenue growth, 27% growth from the six key growth drivers, broad product momentum, positive late-stage clinical results, strong free cash flow and raised 2026 revenue and EPS guidance. The principal negatives were a 6% TEPEZZA sales decline, expected fourth-quarter expense increases, higher full-year other expense guidance and some uncertainty around upcoming symptomatic Sjogren's data and international MariTide reimbursement. Highlights significantly outweighed the lowlights.
View all CH:AMG earnings summariesAMG Net sales Breakdown
- 13.09% Prolia
- 9.92% Enbrel
- 6.66% XGEVA
- 6.65% Repatha
- 63.69% Other
AMG Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 1 | 6 |
| Technical Analysis | 2 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |











